International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-6 doi: 10.5281/zenodo.12787777
Original Research Article
Diagnostic Utility of Pleural Fluid LDH/ADA Ratio in Differentiating Tuberculous from Non-Tuberculous Effusions, Including Malignancy
Published
Nov. 7, 2024
Abstract

Background: Differentiating tuberculous from non-tuberculous pleural effusions remains a diagnostic challenge. This study evaluated the diagnostic utility of pleural fluid LDH/ADA ratio in this differentiation.Methods: This prospective observational study conducted at a tertiary care center included 150 consecutive patients with exudative pleural effusions. Pleural fluid analysis included LDH, ADA, and other biochemical parameters. The diagnostic performance of LDH/ADA ratio was evaluated using ROC curve analysis.Results: The study population comprised 72 tuberculous, 58 malignant, and 20 other non-tuberculous effusions. The median LDH/ADA ratio was significantly lower in tuberculous effusions [6.2 (4.8-7.6)] compared to malignant [20.2 (16.4-24.8)] and other non-tuberculous effusions [15.9 (12.8-19.6), p<0.001]. At the optimal cut-off value of 16.5, the ratio demonstrated sensitivity 92.4%, specificity 89.8%, positive predictive value 90.6%, and negative predictive value 91.8%. Multivariate analysis identified LDH/ADA ratio <16.5 as the strongest independent predictor of tuberculous effusion (adjusted OR: 8.64, 95% CI: 4.82-15.46, p<0.001). Conclusion: The LDH/ADA ratio represents a reliable, cost-effective tool for differentiating tuberculous from non-tuberculous pleural effusions, with excellent diagnostic performance at a cut-off value of 16.5. This ratio can be particularly valuable in resource-limited settings where advanced diagnostic tools may not be readily available.

Recommended Articles
Loading Image...
Volume-5, Issue-6
Citations
1525 Views
160 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved